We are live on ! Find out more
BIVV

Bioverativ Inc. Common Stock
BIVV

Delisted

BIVV was delisted on the 8th of March, 2018.

Back to rankings

467 hedge funds and large institutions have $5.28B invested in Bioverativ Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 467 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $21.4M | Put options by funds: $14.1M

Holders
467
Holders Change
+467
Holders Change %
–
% of All Funds
11.63%
Holding in Top 10
9
Holding in Top 10 Change
+9
Holding in Top 10 Change %
% of All Funds
0.22%
New
467
Increased
–
Reduced
–
Closed
–
Calls
$21.4M
Puts
$14.1M
Net Calls
+$7.29M
Net Calls Change
+$7.29M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$433M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$429M
3
VH
ValueAct Holdings
California
+$418M
4
Primecap Management
Primecap Management
California
+$381M
5
HM
HealthCor Management
New York
+$246M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$479M +$433M +8,786,572 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$475M +$429M +8,717,362 New
VH
3
ValueAct Holdings
California
$462M +$418M +8,476,892 New
Primecap Management
4
Primecap Management
California
$422M +$381M +7,741,094 New
HM
5
HealthCor Management
New York
$272M +$246M +5,000,000 New
State Street
6
State Street
Massachusetts
$228M +$206M +4,188,033 New
ClearBridge Investments
7
ClearBridge Investments
New York
$211M +$191M +3,882,679 New
SIG
8
Senator Investment Group
New York
$170M +$154M +3,124,664 New
JSP
9
Jackson Square Partners
California
$105M +$94.6M +1,920,162 New
Millennium Management
10
Millennium Management
New York
$95.1M +$86M +1,746,489 New
Wells Fargo
11
Wells Fargo
California
$94.1M +$85.1M +1,728,127 New
Norges Bank
12
Norges Bank
Norway
$73.7M +$66.6M +1,352,364 New
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$71.1M +$64.3M +1,305,988 New
Bank of New York Mellon
14
Bank of New York Mellon
New York
$67.5M +$61M +1,238,684 New
Two Sigma Advisers
15
Two Sigma Advisers
New York
$65.8M +$59.5M +1,208,113 New
CCM
16
Camber Capital Management
Massachusetts
$59.9M +$54.2M +1,100,000 New
LCM
17
Laurion Capital Management
New York
$54.3M +$49.1M +996,334 New
Two Sigma Investments
18
Two Sigma Investments
New York
$53.3M +$48.2M +979,332 New
Northern Trust
19
Northern Trust
Illinois
$52.4M +$47.4M +962,960 New
UBS AM
20
UBS AM
Illinois
$48.9M +$44.2M +897,040 New
MWNA
21
Marshall Wace North America
New York
$48M +$43.8M +888,324 New
NM
22
Newtyn Management
New York
$43.6M +$39.4M +800,000 New
WIM
23
Woodford Investment Management
United Kingdom
$43.1M +$39M +791,264 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$42.8M +$38.7M +786,074 New
Morgan Stanley
25
Morgan Stanley
New York
$40.1M +$36.3M +736,110 New
1
2 3 4 5

BIVV Hedge Fund Activity: Q1 2017 in Review

467 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q1 2017, worth a combined $5.28B.

Buyers outnumbered sellers: 467 funds opened new BIVV positions and 0 closed out — a net gain of 467 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $433M.

  • 467 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q1 2017, up from 0 in Q4 2016.
  • Funds reported $5.28B of Bioverativ Inc. Common Stock stock for Q1 2017.
  • 467 funds opened new Bioverativ Inc. Common Stock positions in Q1 2017 and 0 closed out, a net change of +467 holders.
  • The largest Bioverativ Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $433M added.

Based on aggregated 13F filings for Q1 2017.